CatalystMarker
← board

NOTVQ

distress 2/10 · well-funded / low risk
$0.010%today-100% from 52w high
inotiv.com1,945 employeesFounded 1974West Lafayette, INDiagnostics & Research
Revenue
$239M
Liquidity
$15M
Runway
1.4 yrs
Shares 1y
+2%

Price & events

-98.1% over 6M
$0.01$0.29$0.57Jan 26Apr 26Jul 261.1Bfinancing: 8-K material_agreement (2026-06-03)financing: 8-K material_agreement (2026-06-01)financing: 8-K material_agreement (2026-05-18)rating: Lake Street: Buy (2026-02-10)
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-1.8%
1W
-4.7%
1M
-96.3%
3M
-98.1%
6M
-99.5%
1Y
-99.5%
2Y
-100.0%
5Y
-99.9%
All

Overview

Market Cap
$387.26K
Enterprise Value
$-14.79M
Volume
0
52 Week Range
$0.01 – $2.36
Total Shares
34.89M
Float Shares
32.62M
Short %
7.86%
% Held by Insiders
8.63%
% Held by Institutions
13.72%
Beta
3.92

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 34,888,147 · 0 offerings/1y · 0 PIPEs
  • 2026-06-038-Kmaterial_agreement
  • 2026-06-018-Kmaterial_agreement
  • 2026-05-188-Kmaterial_agreement
  • 2025-09-11EFFECTshelf_effective
  • 2025-08-29S-3shelf_registration
  • 2025-07-18424B7offering
  • 2025-01-10424B7offering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • 2026-02-10Lake StreetBuy

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.